{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:05:22Z","timestamp":1751947522213,"version":"3.41.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03044-7","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:15:09Z","timestamp":1751876109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy analysis of endostar combined with chemoradiotherapy and immune checkpoint inhibitors in locally advanced non-small cell lung cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Bo","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaocheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunmin","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"3044_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Ca-Cancer J Clin"},{"key":"3044_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s10495-010-0461-4","volume":"15","author":"V Pongrakhananon","year":"2010","unstructured":"Pongrakhananon V, Nimmannit U, Luanpitpong S, Rojanasakul Y, Chanvorachote P. Curcumin sensitizes non-small cell lung cancer cell Anoikis through reactive oxygen species-mediated Bcl-2 downregulation. Apoptosis. 2010;15:574\u201385. https:\/\/doi.org\/10.1007\/s10495-010-0461-4.","journal-title":"Apoptosis"},{"key":"3044_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. Ca-Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"Ca-Cancer J Clin"},{"key":"3044_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3978\/j.issn.2305-5839.2014.04.05","volume":"2","author":"W Chen","year":"2014","unstructured":"Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in china, 2010. Ann Transl Med. 2014;2:61. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2014.04.05.","journal-title":"Ann Transl Med"},{"key":"3044_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/JTO.0b013e3181f94ad4","volume":"6","author":"JD Hainsworth","year":"2011","unstructured":"Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab\u2009+\u2009carboplatin\/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol. 2011;6:109\u201314. https:\/\/doi.org\/10.1097\/JTO.0b013e3181f94ad4.","journal-title":"J Thorac Oncol"},{"key":"3044_CR6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1056\/NEJMc1900407","volume":"380","author":"SJ Antonia","year":"2019","unstructured":"Antonia SJ. Durvalumab after chemoradiotherapy in stage III Non-Small-Cell lung cancer. Reply. New Engl J Med. 2019;380:990. https:\/\/doi.org\/10.1056\/NEJMc1900407.","journal-title":"New Engl J Med"},{"key":"3044_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L. Non-Small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2024;22:249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","journal-title":"J Natl Compr Canc Ne"},{"key":"3044_CR8","first-page":"2705","volume":"12","author":"W Ge","year":"2011","unstructured":"Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y. Endostar combined with chemotherapy versus chemotherapy alone for advanced nsclcs: a meta-analysis. Asian Pac J Cancer Prev. 2011;12:2705\u201311.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3044_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/s0092-8674(00)81848-6","volume":"88","author":"MS O\u2019Reilly","year":"1997","unstructured":"O\u2019Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277\u201385. https:\/\/doi.org\/10.1016\/s0092-8674(00)81848-6.","journal-title":"Cell"},{"key":"3044_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1477-7819-10-170","volume":"10","author":"B Rong","year":"2012","unstructured":"Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 2012;10:170. https:\/\/doi.org\/10.1186\/1477-7819-10-170.","journal-title":"World J Surg Oncol"},{"key":"3044_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/1759-7714.12626","volume":"9","author":"J An","year":"2018","unstructured":"An J, Lv W. Endostar (rh-endostatin) versus placebo in combination with Vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis. Thorac Cancer. 2018;9:606\u201312. https:\/\/doi.org\/10.1111\/1759-7714.12626.","journal-title":"Thorac Cancer"},{"key":"3044_CR12","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1111\/1759-7714.14188","volume":"12","author":"M Yuan","year":"2021","unstructured":"Yuan M, Zhai Y, Men Y, Wang J, Deng L, Wang W, Bao Y, Yang X, Sun S, Ma Z, Liu Y, Wang J, Zhu H, Hui Z. Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. Thorac Cancer. 2021;12:3208\u201315. https:\/\/doi.org\/10.1111\/1759-7714.14188.","journal-title":"Thorac Cancer"},{"key":"3044_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40487-017-0055-1","volume":"6","author":"K Li","year":"2018","unstructured":"Li K, Shi M, Qin S. Current status and study progress of Recombinant human endostatin in Cancer treatment. Oncol Ther. 2018;6:21\u201343. https:\/\/doi.org\/10.1007\/s40487-017-0055-1.","journal-title":"Oncol Ther"},{"key":"3044_CR14","first-page":"279","volume":"6","author":"JS Greenberger","year":"2000","unstructured":"Greenberger JS. Antitumor interaction of short course endostatin and ionizing radiation. Cancer J. 2000;6:279\u201381.","journal-title":"Cancer J"},{"key":"3044_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020219","author":"C Cunningham","year":"2023","unstructured":"Cunningham C, Bolcaen J, Bisio A, Genis A, Strijdom H, Vandevoorde C. Recombinant endostatin as a potential radiosensitizer in the treatment of non-small cell lung cancer. Pharmaceuticals-Base. 2023. https:\/\/doi.org\/10.3390\/ph16020219.","journal-title":"Pharmaceuticals-Base"},{"key":"3044_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.radonc.2018.10.032","volume":"131","author":"Y Zhai","year":"2019","unstructured":"Zhai Y, Ma H, Hui Z, Zhao L, Li D, Liang J, Wang X, Xu L, Chen B, Tang Y, Wu R, Xu Y, Pang Q, Chen M, Wang L. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent Etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. Radiother Oncol. 2019;131:27\u201334. https:\/\/doi.org\/10.1016\/j.radonc.2018.10.032.","journal-title":"Radiother Oncol"},{"key":"3044_CR17","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2217\/fon-2021-1239","volume":"18","author":"J Zhu","year":"2022","unstructured":"Zhu J, Chen G, Niu K, Feng Y, Xie L, Qin S, Wang Z, Li J, Lang S, Zhuo W, Chen Z, Sun J. Efficacy and safety of Recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer. Future Oncol. 2022;18:1077\u201387. https:\/\/doi.org\/10.2217\/fon-2021-1239.","journal-title":"Future Oncol"},{"key":"3044_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13014-020-01646-9","volume":"15","author":"SL Zhang","year":"2020","unstructured":"Zhang SL, Han CB, Sun L, Huang LT, Ma JT. Efficacy and safety of Recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis. Radiat Oncol. 2020;15:205. https:\/\/doi.org\/10.1186\/s13014-020-01646-9.","journal-title":"Radiat Oncol"},{"key":"3044_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.radonc.2022.06.022","volume":"174","author":"L Chen","year":"2022","unstructured":"Chen L, Tong F, Peng L, Huang Y, Yin P, Feng Y, Cheng S, Wang J, Dong X. Efficacy and safety of Recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer. Radiother Oncol. 2022;174:44\u201351. https:\/\/doi.org\/10.1016\/j.radonc.2022.06.022.","journal-title":"Radiother Oncol"},{"key":"3044_CR20","doi-asserted-by":"publisher","first-page":"10841","DOI":"10.1038\/s41598-022-14222-w","volume":"12","author":"W Jiang","year":"2022","unstructured":"Jiang W, Sun W, Li W, Gao J, Wang H, Zhou W, Liang J, Aa L, Wang L. Real-world treatment pattern and comprehensive comparative effectiveness of endostar plus different chemotherapy in advanced patients with non-small cell lung cancer. Sci Rep-Uk. 2022;12:10841. https:\/\/doi.org\/10.1038\/s41598-022-14222-w.","journal-title":"Sci Rep-Uk"},{"key":"3044_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12957-021-02161-1","volume":"19","author":"L Feng","year":"2021","unstructured":"Feng L, Wang Z, Jing L, Zhou Z, Shi S, Deng R, Liu Y, Meng Q. Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis. World J Surg Oncol. 2021;19:64. https:\/\/doi.org\/10.1186\/s12957-021-02161-1.","journal-title":"World J Surg Oncol"},{"key":"3044_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3892\/mmr.2012.903","volume":"6","author":"K Zhang","year":"2012","unstructured":"Zhang K, Yang S, Zhu Y, Mo A, Zhang D, Liu L. Protection against acute radiation-induced lung injury: a novel role for the anti-angiogenic agent endostar. Mol Med Rep. 2012;6:309\u201315. https:\/\/doi.org\/10.3892\/mmr.2012.903.","journal-title":"Mol Med Rep"},{"key":"3044_CR23","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.ijrobp.2011.09.050","volume":"83","author":"XD Jiang","year":"2012","unstructured":"Jiang XD, Dai P, Wu J, Song DA, Yu JM. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer. Int J Radiat Oncol. 2012;83:1272\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.09.050.","journal-title":"Int J Radiat Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03044-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:15:11Z","timestamp":1751876111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03044-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3044"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03044-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the Helsinki Declaration and approved by the Ethics Committee of Qingdao University Hospital (Approval no. 21-QU-EC-13). All patients provided written and oral informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The subjects gave written informed consent for the publication of any associated data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"1272"}}